Clinical trial NCT03938740: Comparison of Different Insulin Dosing Algorithms Using Hepatic Directed Vesicle-Insulin Lispro and Insulin Degludec
Official title: An Exploratory Randomized Open-Label 2-Arm Comparison of Insulin Dosing Algorithms Using Hepatic Directed Vesicle-Insulin Lispro and Insulin Degludec to Determine Optimum Basal Insulin Dosing Regimens in Type 1 Diabetes Mellitus Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Diabetes Mellitus, Type 1
Lead sponsor: Diasome Pharmaceuticals
Sponsor class: INDUSTRY
First posted: 2019-05-06
Enrollment: 61
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Multi-center, open-label, multiple dose safety, tolerability and efficacy study

Detailed description: This is a 24-week, open-label, multiple dose safety, tolerability and efficacy study. There is a 12-week run-in phase when all subjects receive Insulin Lispro and Insulin Degludec for 12 weeks. After completing the run-in period, subjects then are randomized to a treatment group of either HDV- Insulin lispro + Insulin Degludec (Degludec dose reduced by 40%) or HDV-Insulin lispro+ Insulin Degludec (Degludec dose reduced by 10%) for 12 weeks of treatment.

Eligibility criteria: Inclusion Criteria:

1. Male or female of age 18 to 65 years, inclusive.
2. If female of child-bearing potential, must agree for the duration of the study. to use adequate contraceptive measures, such as, intra-uterine device \[IUD\], oral or injectable contraceptives, or barrier method plus spermicide.
3. Has at Screening been diagnosed as T1DM for at least 12 months.
4. Has at Screening C-peptide ≤0.8 ng/mL (single retest allowed).
5. Has at Screening been on treatment with rapid analog insulin for the previous six (6) months.
6. Has at Screening willingness to use continuous glucose monitoring (CGM) technology throughout study.
7. Is, for the duration of the study, willing to use insulin lispro as the only analog bolus insulin and insulin degludec as the only basal insulin.
8. Has at Screening a BMI ≥18.0 kg/m2 and ≤33.0 kg/m2.
9. Has at Screening HbA1c ≥6.5% and ≤8.5%.

Exclusion Criteria:

1. Has known or suspected allergy to any component of any of the study drugs in this trial.
2. Is, at Screening, pregnant or breast-feeding, or intends to become pregnant at any time during the duration of the study.
3. Has, at Screening, as judged by the Site Investigator, a history or current evidence of any of the following complications of diabetes: proliferative retinopathy or maculopathy, severe neuropathy (in particular, autonomic neuropathy), symptomatic gastroparesis.
4. Is, at Screening, judged by the Site Investigator to have a current addiction to alcohol or substances of abuse.
5. Is, at Screening, using one or more drugs that may interfere with the interpretation of trial results or are known to cause clinically relevant interference with insulin action, glucose utilization, or recovery from hypoglycemia (e.g., beta blockers, systemic corticosteroids at pharmacologic doses, cancer chemotherapies.).
6. Has at Screening any of the following findings, unless approved by both the Site Investigator and the Medical Monitor:

   * Uncontrolled hypertension, defined as diastolic blood pressure ≥ 100 mmHg and/or systolic blood pressure ≥ 160 mmHg after 5 minutes in the sitting position;
   * History of or findings on EKG of cardiac arrhythmia or conduction defect;
   * Clinically significant abnormalities on Screening laboratory studies
7. Has, within one (1) month prior to Screening, used either oral anti-diabetic medication or non-insulin anti-diabetic injection therapies (e.g. SGLT-2 inhibitors, pramlintide, GLP-1 agonists, etc.).
8. Has, within one (1) month prior to Screening, received any investigational drug.
9. Has, within two (2) months prior to Screening, used an insulin pump delivery system.
10. Has, within three (3) months prior to Screening, smoked tobacco or used any smokeless tobacco or nicotine delivery system (inhaled, oral or buccal).
11. Has at Screening, as judged by the Site Investigator, any condition (intrinsic or extrinsic) that could reasonably be expected to interfere with trial participation, confound evaluation of the data, or pose additional risk to adhering to the study protocol. Examples of such conditions include but are not limited to:

    * Clinically significant active disease of the gastrointestinal, cardiovascular, hepatic, neurological, renal, genitourinary, or hematological systems;
    * History of such an illness or disease
    * Diminished mental capacity, psychological or behavioral dysfunction, unwilling or resistant to protocol requirements, language barriers

Primary outcomes:
measure: Basal, bolus and total insulin doses (UOM=units) during the last 2 weeks of the treatment period
timeFrame: 24 weeks
measure: Basal/bolus ratios during the last 2 weeks of the treatment period
timeFrame: 24 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: San Mateo
country: United States
facility: Mills-Peninsula Medical Center, Diabetes Research Institute
state: California
city: Aurora
country: United States
facility: Barbara Davis Center for Diabetes
state: Colorado
city: Atlanta
country: United States
facility: Atlanta Diabetes Associates
state: Georgia
city: Roswell
country: United States
facility: Endocrine Research Solutions, Inc.
state: Georgia
city: Morehead City
country: United States
facility: Diabetes & Endocrinology Consultants, PC
state: North Carolina
city: Austin
country: United States
facility: Texas Diabetes & Endocrinology, PA
state: Texas
city: Round Rock
country: United States
facility: Texas Diabetes & Endocrinology, PA
state: Texas
Study officials:
affiliation: Diasome Pharmaceuticals
name: Marc Penn, MD, PhD
role: STUDY_DIRECTOR
References: